ReviewCancer metastasis reviews2026
Antibody-drug conjugates in cancer therapy: do we need biomarkers? A comprehensive review.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Bispecific Antibodies in Oncogene-Driven Non-Small-Cell Lung Cancer: Evolving Roles in Treatment Sequencing and Resistance Management.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy, yet a fundamental clinical contradiction remains: while some ADCs require strict companion diagnostic testing, others demonstrate robust efficacy in biomarker-negative tumors. This review investigates the underlying mechanisms of this discrepancy, proposing that ADC linker cleavability is the primary determinant of both biomarker dependence and systemic toxicity profiles. By analyzing data from 40 clinical trials encompassing 7879 patients, we observed a distinct dichotomy based on linker design. ADCs utilizing noncleavable linkers function in a strictly biomarker-dependent manner, correlating with a targeted safety profile (34% severe toxicity rate) but relying entirely on antigen-mediated internalization. Conversely, ADCs with cleavable linkers facilitate premature payload release in the systemic circulation and tumor microenvironment. This enables a potent, biomarker-independent bystander effect-achieving a 29.7% tumor response rate even without target expression-but at the cost of significantly increased off-target systemic toxicities (47% severe toxicity rate). Recognizing this inherent trade-off between antitumor potency and safety, we further explore the development of next-generation, conditionally cleavable linkers. These advanced platforms are engineered for selective activation exclusively within the tumor microenvironment. We conclude that transitioning towards conditionally released linkers is essential to balance efficacy and systemic toxicity, optimizing the therapeutic index and fully realizing the potential of the "magic bullet."
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.